WIN-B

CLINICAL STUDY TO EVALUATE DEBIO0123 + SACITUZUMAB GOVITECAN COMBINATION IN TNBC OR HR+/HER2- ADVANCED BREAST CANCER (WIN-B)

https://clinicaltrials.gov/study/NCT06647290

Breast cancer

76 (Ib: 8, II: 25)

Ib/II

Spain, UK, US

Recruitment

CLINICAL TRIAL DETAILS

THE PRIMARY OBJECTIVE IS TO EVALUATE DEBIO 0123'S RP2D WHEN ADMINISTERED IN COMBINATION WITH SACITUZUMAB GOVITECAN, SAFETY AND EFFICACY OF THIS COMBINATION THERAPY IN ADVANCED/METASTATIC BREAST CANCER PATIENTS. PATIENTS AGED ≥ 18 YEARS WITH TNBC OR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER RELAPSING AFTER ONE OR TWO LINES OF TREATMENT ARE ELIGIBLE TO PARTICIPATE IN THE STUDY.

TUMOR TYPE

PHASE

SITES

COUNTRY

STATUS

PRESS RELEASE

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial: https://www.medsir.org/post/medsir-debiopharm-announce-the-first-patient-dosed-in-the-win-b-trial

SCIENTIFIC IMPACT

ASCO 2025 poster: https://www.medsir.org/_files/ugd/39f166_c4a74de06570479fad3417c99fd5cd1b.pdf | ASCO 2025 lay language summary: https://www.medsir.org/_files/ugd/39f166_6cae5636fbaa459fa20d757794a37e66.pdf

BLOG ARTICLES RELATED

PHERGAIN SITES

Hospital Arnau de Vilanova de Valencia (Spain) | Hospital Beata María Ana (Spain) | Hospital Universitario Virgen de la Victoria (Spain) | Beatson West of Scotland Cancer Centre (UK) | Hospital Universitari Dexeus (Spain) | Hospital Universitario Clínico San Cecilio de Granada (Spain) | Velindre University NHS Trust (UK) | Hospital Universitario San Juan Alicante (Spain)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley